Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Stock-based compensation expense in cost of sales by Year
Stock-based compensation expense in cost of sales ($M) ($M)
Moderna Stock-based compensation expense in cost of sales: $26M in FY2025, up 4.0% from a year earlier.
Latest, FY2025
26
Period ended Dec 31, 2025
Change on a year earlier
+4.0%
25 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 14 (Stock-Based Compensation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-based compensation expense in cost of sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26 | +4.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 25 | -32.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 37 | -17.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 45 | +104.5% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 22 | – | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). Moderna Stock-based compensation expense in cost of sales ($M), annual FY2019–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-sbc
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.